Podymova S D, Nadinskaia M Iu
Klin Med (Mosk). 1998;76(10):45-8.
Heptral (S-adenosine-L-methionine) was given to 32 patients with chronic diffuse diseases of the liver and intrahepatic cholestasis. 16 of them had primary biliary cirrhosis (PBC). Phase I of the treatment lasted 16 days when the drug was injected intravenously in a dose 800 mg/day. It was followed by phase 2--1600 mg/day taken for 16 days. A response was registered in the majority of patients. They had relieved symptoms of asthenia, skin pruritus, jaundice. The patients with liver cirrhosis and chronic hepatitis exhibited a statistically significant fall in ALT, AST and GGTP. PBS patients showed insignificant lowering of cholesterol, bilirubin. No resistance was noted in repeated courses. Heptral tolerance was satisfactory.
给32例患有慢性弥漫性肝病和肝内胆汁淤积的患者使用了喜疗妥（S-腺苷-L-蛋氨酸）。其中16例患有原发性胆汁性肝硬化（PBC）。治疗的第一阶段持续16天，在此期间药物以800毫克/天的剂量静脉注射。随后是第二阶段——每天服用1600毫克，持续16天。大多数患者出现了反应。他们的乏力、皮肤瘙痒、黄疸症状得到缓解。肝硬化和慢性肝炎患者的谷丙转氨酶（ALT）、谷草转氨酶（AST）和γ-谷氨酰转肽酶（GGTP）有统计学意义的下降。原发性胆汁性肝硬化患者的胆固醇、胆红素略有降低。重复疗程未发现耐药性。喜疗妥的耐受性良好。
